Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

Autor: Camille Tessier, Richard LeBlanc, Jean Roy, Sabrina Trudel, Julie Côté, Marc Lalancette, Jean‐Samuel Boudreault, Émilie Lemieux‐Blanchard, Rayan Kaedbey, Michel Pavic

Publikováno v: Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)

Abstract Background Plasma cell leukemia (PCL) is a rare monoclonal gammopathy, associated with short survival. Because of its very low incidence, only a few cohorts have been reported and thus, information on this disease is scarce. The goal of this

Externí odkaz: https://doaj.org/article/41fd1e661a10445ab6a281d4f98c7702

Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation

Autor: Marie-Élaine Plante, Xue Feng, Jean-Samuel Boudreault

Publikováno v: Leukemia & Lymphoma. :1-9

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a58c1ccb06abfdcb80d1593689ba6e9f
https://doi.org/10.1080/10428194.2023.2203790

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

Autor: Flechere Fortin, Jean-Samuel Boudreault, Rayan Kaedbey, Michel Pavic, Vincent Ethier, Camille Tessier, Thomas Allard

Publikováno v: Current Oncology, Vol 28, Iss 188, Pp 2029-2039 (2021)
Current Oncology
Volume 28
Issue 3
Pages 188-2039

Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931ffe69d3c149c89f794750131b1494
https://www.mdpi.com/1718-7729/28/3/188

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

Autor: Philippe Moreau, Pierre Gallas, Pierre Peterlin, Céline Bossard, Cyrille Touzeau, Anne-Sophie Moreau, Thierry Guillaume, A. Lok, Patrice Chevallier, Benoit Tessoulin, N. Blin, J. Moynard, V. Dubruille, F. Perrin, E. Delande, Thomas Gastinne, Patrick Thomaré, Steven Le Gouill, Alice Garnier, Jean-Samuel Boudreault, Béatrice Mahé

Publikováno v: Annals of Hematology. 96:943-950

The DHAP regimen (high-dose cytarabine in combination with dexamethasone and cisplatin) with or without rituximab (DHAP+/−R) is one of the most common regimens in daily practice. It is considered the standard treatment for relapse or refractory Hod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9561f01b3a7f56e589f4099846b3526
https://doi.org/10.1007/s00277-017-2981-2

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Autor: Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Uddin Ghori, Mohammed Z H Farooqui, Patricia Marinello, Jesus San-Miguel, Andrew Lim, Trish Walker, Andrew Nicol, Donna Reece, Mohamed Elemary, Jean Samuel Boudreault Pedneault, Michel Attal, Katja Weisel, Monika Engelhardt, Andreas Mackensen, John Quinn, Amos Cohen, Hila Magen-Nativ, Noam Benyamini, Alessandra Larocca, Morio Matsumoto, Shinsuke Iida, Takayuki Ishikawa, Yukio Kondo, Kazutaka Sunami, Kiyoshi Ando, Takanori Teshima, Takaaki Chou, Hiromi Iwasaki, Hirokazu Miki, Itaru Matsumura, Yasushi Onishi, Koji Izutsu, Masahiro Kizaki, Anupkumar George, Hillary Blacklock, David Simpson, Anders Waage, Olga Samoilova, Evgeniy Nikitin, Tatiana Chagorova, Andrew McDonald, Moosa Patel, Albert Oriol Rocafiguera, Jesus San Miguel Izquierdo, Maria Mateos, Matthew Streetly, Peter Forsyth, Graham Jackson, Stephen Jenkins, Robert Rifkin, Habte Yimer, Robert McCroskey, Danko Martincic, Stefano Tarantolo, Sarah Larson, Yacoub Faroun, Jennifer Vaughn, Rachid Baz, Gene Saylors, Amarendra Neppalli, Anastasios Raptis, Henry Fung, Maxwell Janosky, Don Stevens, Morton Coleman, Dennis Costa, Scott Cross, Suzanne Fanning, Daniel Farray Berges, Thomas Harris, Ira Zackon, Djordje Atanackovic, Kelvin Lee, Ira Oliff, Wes Lee, William Bensinger, Jose Lutzky, Ari Baron, Fadi Hayek, Eli Kirschner, Neeraj Bharany, Lindsay Overton, Siva Mannem, Allyson Harroff, Sharad Jain, Tammy Roque, Kristi McIntyre, Christopher K Yasencha, William Houck

Publikováno v: Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment efficacy. KEYNOTE-18

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9587f7fc06343c5e2bc999bbff275d45
http://hdl.handle.net/10852/77065